^
Association details:
| Biomarker: | BRAF-MAD1L1 fusion |
|---|---|
| Cancer: | Rhabdomyosarcoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Case report: BRAF-MAD1L1 and BRAF-ZC3H7A: novel gene fusion in Rhabdomyosarcoma and Lung adenocarcinoma
Excerpt:
...the patient received anlotinib hydrochloride (12 mg 1/day, d1-d14 for 3 weeks). In December 2018, pelvic tumors increased slightly, and new liver metastases were observed with PD....First generation sequencing (Sanger) conrmed BRAF-MAD1L1 fusion in the RMS patient.
DOI:
10.21203/rs.3.rs-58002/v1
